AYTU Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
12.4M
-18.2%
15.2M
+9.2%
13.9M
-8.2%
15.1M
-18.0%
18.5M
Cost of Revenue
4.8M
-13.2%
5.5M
+17.8%
4.7M
-3.7%
4.9M
-13.5%
5.6M
Gross Profit
7.6M
-21.0%
9.6M
+4.8%
9.2M
-10.4%
10.3M
-19.9%
12.8M
Operating Expenses
11.7M
+0.6%
11.6M
+8.5%
10.7M
-40.2%
17.9M
+72.1%
10.4M
R&D
0
0
0
-100.0%
216.0K
+33.3%
162.0K
SG&A
10.9M
-1.5%
11.1M
+8.0%
10.2M
+20.9%
8.5M
-8.9%
9.3M
Operating Income
-4064000
-106.3%
-1970000
-31.0%
-1504000
+80.3%
-7623000
-414.9%
2.4M
EBITDA
-2943000
-171.2%
-1085000
-54.8%
-701000
-136.2%
1.9M
-47.8%
3.7M
Net Income
-5618000
+46.9%
-10584000
-638.6%
2.0M
+109.9%
-19818000
-596.2%
4.0M
EPS (Basic)
$-0.53
+49.5%
$-1.05
-600.0%
$0.21
+107.2%
$-2.92
-549.2%
$0.65
EPS (Diluted)
$-0.53
+49.5%
$-1.05
-1212.5%
$-0.08
$0.21
Shares (Diluted)
10.5M
+4.7%
10.0M
-48.5%
19.5M
8.2M
AYTU BioPharma (AYTU) — Financials